TPG Buys 35% Stake in SCHOTT Poonawalla from SII in Strategic Investment Deal.

Economy Business

In May 2025, Germany-based SCHOTT Pharma AG & Co. announced that United States (USA)-based global investment firm TPG Inc. has signed a binding agreement to acquire a 35% stake in its Indian joint venture (JV), SCHOTT Poonawalla Private Limited, from Pune (Maharashtra)-based Serum Institute of India Private Limited (SII), a key part of the Cyrus Poonawalla Group.


      - This strategic acquisition aims to scale pharmaceutical packaging innovations and further strengthen the JV’s position in the global healthcare ecosystem.

      - The transaction is routed through TPG Growth, TPG’s middle-market and growth equity platform. Novo Holdings A/S, based in Denmark, has joined as a co-investor, showcasing a strong global interest in India’s pharma packaging sector.

     

Main Point :-   (i) After the deal, SCHOTT Pharma will retain its 50% stake in the joint venture, while SII will hold a minority stake, ensuring continued collaboration across the entities.

      (ii) The partnership is set to enhance SCHOTT Poonawalla’s capacity to deliver high-quality pharmaceutical packaging solutions that meet international standards, reinforcing its role in supporting the global healthcare value chain.

(iii) Serum Institute of India (SII), part of the Cyrus Poonawalla Group, is the world’s largest vaccine manufacturer by volume. It was founded in 1966 by Dr. Cyrus Poonawalla.

          ____________________________